Altimmune, Inc. (NASDAQ:ALT) Short Interest Update

Altimmune, Inc. (NASDAQ:ALT) was the target of a significant drop in short interest in January. As of January 31st, there was short interest totalling 23,320,000 shares, a drop of 5.2% from the January 15th total of 24,590,000 shares. Based on an average daily trading volume, of 3,190,000 shares, the days-to-cover ratio is currently 7.3 days.

Institutional Trading of Altimmune

A number of hedge funds and other institutional investors have recently modified their holdings of ALT. Bellevue Group AG raised its position in Altimmune by 43.9% during the third quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock valued at $5,303,000 after buying an additional 263,660 shares during the period. Virtu Financial LLC acquired a new position in Altimmune during the third quarter valued at $674,000. Barclays PLC raised its position in Altimmune by 93.0% during the third quarter. Barclays PLC now owns 155,741 shares of the company’s stock valued at $956,000 after buying an additional 75,064 shares during the period. Charles Schwab Investment Management Inc. raised its position in Altimmune by 2.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock valued at $1,299,000 after buying an additional 4,772 shares during the period. Finally, Stifel Financial Corp raised its position in Altimmune by 77.4% during the third quarter. Stifel Financial Corp now owns 17,752 shares of the company’s stock valued at $109,000 after buying an additional 7,746 shares during the period. Institutional investors own 78.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. UBS Group assumed coverage on Altimmune in a research report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research note on Wednesday, February 5th. Finally, Stifel Nicolaus began coverage on Altimmune in a research note on Wednesday, January 8th. They set a “buy” rating and a $18.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Altimmune currently has a consensus rating of “Buy” and a consensus price target of $20.83.

Altimmune Stock Performance

Shares of ALT stock opened at $6.78 on Thursday. Altimmune has a 1 year low of $5.28 and a 1 year high of $14.84. The stock has a fifty day moving average of $7.15 and a two-hundred day moving average of $7.18. The firm has a market capitalization of $482.19 million, a PE ratio of -4.37 and a beta of 0.19.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.